J Korean Ophthalmol Soc.  2009 Sep;50(9):1301-1307. 10.3341/jkos.2009.50.9.1301.

Evaluation of Mood Disturbance in Korean Patients With Dysthyroid Ophthalmopathy

• Paik JS
• Yang SW

• KMID: 2212611
• DOI: http://doi.org/10.3341/jkos.2009.50.9.1301

Abstract

PURPOSE
to measure mood disturbance of Korean patients with dysthyroid ophthalmopathy according to the severity of ophthalmopathy. METHODS: Fifty patients with dysthyroid ophthalmopathy (mean age: 46.6+/-12.1 years; 32 female patients and 18 male patients) were included, and classified into 2 groups according to the disease severity. Twenty-five patients were classified with moderate/severe diseases (study group) and 25 patients classified with negligible/mild disease (control group). All patients completed a mood survey of 65 questions to assess differences in the degree of emotional distress. RESULTS: Analysis of each group showed that patients with moderate/severe ophthalmopathy had significantly greater emotional distress than patients with negligible/mild ophthalmopathy according to the Korean Profile of Mood States mean total score (p=0.03). In particular, patients with disfigurement (proptosis predominant group) had significantly worsen emotional distress compared with the control group (p=0.007), whereas patients with diplopia (diplopia predominant group) had no significant difference compared with the control group (p=0.60). CONCLUSIONS: Patients with moderate to severe ophthalmopathy have significant emotional distress, and severe mood disturbance especially when disfiguring signs are predominant. The psychological burden of the disease should be recognized, and routine follow-up recommended along with additional psychiatric consultation.

Keyword

Dysthyroid ophthalmopathy; Mood disturbance

MeSH Terms

Diplopia
Female
Follow-Up Studies
Graves Ophthalmopathy
Humans
Male

Reference

References

1. Burch HB, Wartofsky L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev. 1993; 14:747–93.

2. Weetman AP. Thyroid-associated eye disease: pathophysiology. Lancet. 1991; 338:25–8.

3. Wiersinga WM, Prummel MF. An evidence-based approach to the treatment of Graves’ ophthalmopathy. Endocrinol Metab Clin North Am. 2000; 29:297–319.

4. Gerding MN, van der Meer JW, Broenink M, et al. Association of thyrotropin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 2000; 52:267–71.

5. Bahn RS. Understanding the immunology of Graves’ ophthalmopathy: is it an autoimmune disease? Endocrinol Metab Clin North Am. 2000; 29:287–96.

6. Terwee CB, Gerding MN, Dekker FW, et al. Delopment of a disease specific quality of life questionnaire for patients with Graves’ ophthalmopathy: the GO-QOL. Br J Ophthalmol. 1998; 82:773–9.

7. Terwee CB, Gerding MN, Dekker FW, et al. Test-retest reliability of the GO-QOL: a disease-specific quality of life questionnaire for patients with Graves’ ophthalmopathy. J Clin Epidemiol. 1999; 52:875–84.

8. Terwee CB, Dekker FW, Mourits MP, et al. Interpretation and validity of changes in scores on the Graves’ ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol (Oxf). 2001; 54:391–8.

9. Egle UT, Kahaly GJ, Petrak F, et al. The relevance of physical and psychosocial factors for the quality of life in patients with thyroid-associated orbitopathy (TAO). Exp Clin Endocrinol Diabetes. 1999; 107:S168–71.

10. Bartley GB, Fatourechi V, Kadrmas EF, et al. Long-term followup of Graves’ ophthalmopathy in an incident cohort. Ophthalmology. 1996; 103:958–62.

11. Gerding MN, Terwee CB, Dekker FW, et al. Quality of life in patients with Graves’ ophthalmopathy is markedly decreased: measurement by the Medical Outcomes Study instrument. Thyroid. 1997; 7:885–9.

12. Farid M, Roch-Levecq AC, Levi L, et al. Psychological disturbance in graves ophthalmopathy. Arch Ophthalmol. 2005; 123:491–6.

13. Kahaly GJ, Petrak F, Hardt J, et al. Psychological morbidity of Graves's orbitopathy. Clin Endocrinol (Oxf). 2005; 63:395–402.

14. Yuen KS, Cheng AC, Chan WM. Graves ophthalmopathy and mood disturbance. Arch Ophthalmol. 2006; 124:426–7.

15. McNair DM, Lorr M, Droppleman LF. POMS Manual: Profile of Mood States (Revised). San Diego, Calif: Educational and Industrial Testing Service;1992.

16. Kim EJ. Reliabilities and Validities of the POMS (Profile of Mood States, Korean edition) for the normal high school and college students. Chungbuk national university: department of medicine, graduate school, the thesis for master degree;2001.

17. Hollingshead AB. Two factor index of social position. New Haven, USA: Yale university press;1957.

18. Lima WT, Perches M, Valera FC, Demaro RC. Orbital endoscopic decompression in Graves ophthalmopathy. Braz J Otorhino-laryngol. 2006; 72:283–7.

19. Chang EL, Piva AP. Temporal fossa orbital decompression for treatment of disfiguring thyroid-related orbitopathy. Ophthalmology. 2008; 115:1613–9.

20. Ben Simon GJ, Schwarcz RM, Mansury AM, et al. Minimally invasive orbital decompression: local anesthesia and hand-carved bone. Arch Ophthalmol. 2005; 123:1671–5.

21. Lyons CJ, Rootman J. Orbital decompression for disfiguring exophthalmos in thyroid orbitopathy. Ophthalmology. 1994; 101:223–230.

22. Oh HS, Chang YH, Lee JB. Strabismus surgery for thyroid ophthalmopathy. J Korean Ophthalmol Soc. 2002; 43:1718–23.

23. Woo KI, Kim YD, Lee SY, et al. The clinical characteristic of thyroid orbitopathy in thyroid dysfunction patients in Korea. J Korean Ophthalmol Soc. 2008; 49:1387–96.

24. Wakelkamp I, Bakker O, Baldeschi L, et al. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves’ ophthalmopathy patients. Clin Endocrinol (Oxf). 2003; 58:280–7.

25. Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor auto-antibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006; 91:3464–70.